TET2 and myeloproliferative neoplasm: There was no relation between the occurrence of the TET2 mutation and age, JAK2V617F allele burden, frequency of organomegaly, fibrosis of the marrow, hematologic indices, as well as thrombotic or hemorrhagic complications in all MPN patients [13].